The present study was a secondary analysis of the ThIlo trial, a prospective randomized multicenter trial assessing the efficacy of inhaled iloprost for the prevention of the development and progression of ARDS in critically ill patients. Study design and recruitment are described elsewhere [14 (link)]. The study was approved by the Institutional Review Board of the Research Ethics Committee of the University of Tübingen (899/2018AMG1) and the corresponding ethical review boards of all the participating centers. The trial was approved by the Federal Institute for Drugs and Medical Devices (BfArM, EudraCT No. 2016-003168-37) and registered at clinicaltrials.gov (NCT03111212). All patients provided written informed consent prior to enrollment.
Iloprost treatment did not show any significant effect on the outcomes of these patients; therefore, a secondary analysis was performed.
Iloprost treatment did not show any significant effect on the outcomes of these patients; therefore, a secondary analysis was performed.
Free full text: Click here
